Skip to main content
Home
1L metastatic/recurrent NSCLC (with chemo)
1L metastatic/recurrent NSCLC
1L unresectable malignant pleural mesothelioma
1L advanced ccRCC
2L+ advanced HCC
Metastatic/unresectable melanoma
2L+ MSI-H/d-MMR metastatic/recurrent CRC
1L unresectable advanced/recurrent/metastatic ESCC
Lung cancer
1L unresectable malignant pleural mesothelioma
1
Lung cancer
1L unresectable malignant pleural mesothelioma
1
Fixed
nivolumab dosing (Q3W)
Weight-based
nivolumab dosing (Q2W)
Fixed
nivolumab dosing (Q3W)
Click to zoom
Weight-based
nivolumab dosing (Q2W)
Click to zoom
1L, first-line; IV, intravenous; PD, progressive disease; QxW, every x weeks.
1. Opdivo
®
(nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.